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Abstract 
 
Introduction: Prescribing restrictions for angiotensin receptor blockers (ARBs) limited their utilisation 
in Austria. Recently generic losartan became available with its prescribing restrictions lifted whilst still 
in place for patented ARBs. Objectives: Assess the impact of the lifting of the prescribing restriction 
on (a) utilisation of losartan in ambulatory care versus other single ARBs, (b) expenditure per DDD 
(defined daily dose) of losartan as well as total ARB expenditure, and (c) utilisation of ARB 
combinations. Lastly, suggest potential measures that could be introduced to further enhance ARB 
prescribing efficiency. Methodology: Quasi-experimental study of the utilisation of different ARBs 
alone or in fixed dose combinations (FDCs) using a segmented time series. Utilisation measured in 
'''VGHILQHGDVµthe average maintenance dose of a drug when used in its major indication in 
adults¶Costs measured as total expenditure for different ARBs as well as their expenditure/ DDD. 
Results: Losartan utilisation increased significantly following the withdrawal of prescribing restrictions 
(P>0.001). Utilisation of patented ARBs also increased, but the growth rate was appreciably reduced 
once restrictions were lifted for losartan (P>0.01). As a result, total expenditure of single ARBs 
increased but at an appreciably lower rate than utilisation, helped by total expenditure/ DDD for 
losartan declining by 78% over the study period. There was continuing appreciable utilisation of 
FDCs. Conclusions: Lifting of prescribing restrictions for losartan significantly enhanced its utilisation, 
increasing ARB prescribing efficiency, providing direction to other European authorities. Additional 
reforms are needed to further switch utilisation from other ARBs to additionally improve prescribing 
efficiency. These are being considered as more ARBs lose their patents. 
 
Introduction 
 
Scrutiny over pharmaceutical expenditure has increased across Europe in recent years, with 
expenditure generally rising faster than other components in ambulatory care, resulting in 
pharmaceutical expenditure typically the largest cost component in ambulatory care [1-5]. This is set 
to continue unless addressed, driven by well known factors including the continued launch of new 
premium priced medicines, rising patient expectations and a growing elderly population [2-4, 6-9]. As 
a result, multiple supply- and demand-side reforms have been introduced across Europe in an effort 
to maintain the European ideals of equitable and comprehensive healthcare. In the case of existing 
drugs, these include initiatives to lower the price of molecules once multiple sources become 
available, compulsory price reductions, as well as reference pricing for the molecule (Anatomical 
Therapeutic Classification ± ATC - Level 5 [101]), the class (ATC level 4) or therapeutic area (ATC 
Level 3) [9-19]. Demand-side measures include initiatives to enhance the prescribing or dispensing of 
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generics versus originators incorporating voluntary or compulsory International Non-proprietary 
Nomenclature (INN) prescribing, compulsory substitution or substitution targets [1-4,7-9,11-17,19]; as 
well as  increase the prescribing of generics versus premium priced patented products in a class or 
related class. Initiatives include guidelines, prescribing guidance, academic detailing, benchmarking, 
prescribing targets, financial incentives for all key stakeholder groups as well as prescribing 
restrictions [1-4,7-9,11-15,18-27].  
 
Multiple demand-side measures are typically needed to improve prescribing efficiency as seen in 
Austria (particularly statins and renin-angiotensin inhibitor drugs), Sweden and the UK (England and 
Scotland) for the proton pump inhibitors (PPIs), statins and the renin-angiotensin inhibitor drugs ( 
Angiotensin converting enzyme inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs), 
versus Ireland and Portugal (Table 1), with their more limited demand-side measures to combat 
commercial pressures and encourage the prescribing of generics [1,4,7-9,11,12,14,15,20-23]. In the 
case of Ireland in particular, typically the utilisation of multiple sourced PPIs and statins went down, 
and the prescribing of patented PPIs and statins increased, once generics became available, 
appreciably adding to their prescribing costs versus Sweden and the UK [8,9]. 
 
Table 1 ± Changes in utilisation patterns for PPIs, statins and renin-angiotensin drugs (2010 DDDs) 
versus reimbursed expenditure 2007 vs. 2001 [7-9,12,18,20-23] 
 
Country Change in utilisation 2007 vs. 
2001 (DDDs) 
Change in expenditure 2007 
vs. 2001 
Austria ± PPIs 3.6 fold increase 2.1 fold increase* 
Austria ± statins Approximately 2.4 fold increase 3% decrease* 
Austria ± ACEIs/ ARBs 69% increase 23% increase 
England ± PPIs 2.3 fold increase 36% reduction 
England ± statins 5.1 fold increase 20% increase 
Ireland** ± PPIs 2.4 fold increase 2.6 fold increase 
Ireland** ± statins 7.3 fold increase 4.9 fold increase 
Portugal ± PPIs 4.3 fold increase 2.3 fold increase 
Portugal ± statins 5.6 fold increase 2.9 fold increase 
Portugal ± ACEIs/ ARBs 72% increase 41% increase 
Scotland ± PPIs 2.3 fold increase 52% reduction 
Scotland ± statins 4.9 fold increase 16% increase 
Scotland ± ACEIs/ ARBs 2.6 fold increase 20% increase 
Sweden ± PPIs 53% increase 49% reduction 
Sweden ± statins 3.2 fold increase 39% reduction 
Sweden ± ACEIs/ ARBs 92% increase 20% increase 
NB * = Total Expenditure, ** GMS Population (greater co-morbidity than total population). DDDs = defined daily 
doses, proton pump inhibitors = PPIs, Angiotensin converting enzyme inhibitors = ACEIs, Angiotensin Receptor 
Blockers = ARBs 
  
A recent study in Scotland showed that the reforms continued to enhance prescribing efficiency for 
the PPIs and statins, with expenditure/ 1000 inhabitants/ year in 2010 for the PPIs decreasing by 56% 
compared with 2001 levels despite a 3 fold increase in utilisation (in DDDs - defined daily doses) [15]. 
Similarly, reimbursed expenditure for the statins only increased by 7% in 2010 compared with 2001 
levels despite a 6.2 fold increase in utilisation during this period [15].    
 
Austria is no exception. Supply side measures for existing drugs include pricing regulations for 
generics and originators once multiple sourced products are available as well as voluntary reference 
pricing in a class once standards become available as generics [1,7,9,12,21,22]. Under the reforms, 
the first generic must be priced a minimum of 48% below the originator product to be reimbursed, the 
second generic at least 15% lower than the first and the third generic at least 10% lower than the 
 3 
 
second to be reimbursed. This equates to at least 60% below the originator price once the third 
generic is launched. This establishes the benchmark price for all branded generics and the originator 
product within 3 months of the entry of the third generic (Figure 1) [1,7,9,21,22]. Subsequent branded 
generics must be priced at least 10 Euro cents per pack below the previous pack to be reimbursed. 
Companies do this to gain market share, with IT systems highlighting the cheapest branded generics 
to physicians, building on quarterly publications sent by insurance companies to ambulatory care 
physicians again highlighting the cheapest branded generic, DVZHOODVSK\VLFLDQV¶SUHVFULELQJFRVWV
benchmarked against each other coupled with financial incentives to prescribe the cheapest branded 
generic [1,21,22]. 
 
Figure 1 ± Pricing policy for both originators and generics in Austria once multiple sourced products 
become available (reproduced with kind permission of Expert Review) assuming the originator was 
SULFHGDW¼SDFNEHIRUHORVLQJLWVSDWHQW± Redrawn from reference 22] 
 
 
 
 
This led for instance to total expenditure/ DDD for generic ACEIs up to 77% below pre-patent 
originator prices, generic omeprazole 77% below, and generic simvastatin 72% below pre-patent loss 
prices, by the end of 2007 [21,22]. The combined Social Health Insurance in Austria (Hauptverband 
der Österreichischen Sozialversicherungsträger - HVB) also seeks voluntary price reductions from 
companies with existing patented products in a class  where there are seen as interchangeable and 
some are already available as generics [1,21]. This initiative already resulted in appreciable 
DFFXPXODWHGVDYLQJVRI¼PQSHU\HDULQ>@2WKHUZLVHSUHVFULELQJUHVWULFWLRQVDUH
introduced for existing patented products or delisting [1,21]. The manufacturers of existing patented 
PPIs voluntarily lowered their prices to avoid restrictions once generic omeprazole became available 
[21]. However, the situation was different with the manufacturer of atorvastatin, leading to its 
prescribing being restricted to patients not achieving target lipid levels with generic statins; otherwise 
100% co-payment [8,9,20,21,23]. This built on existing prescribing restrictions for rosuvastatin [1,21]. 
As a result, the utilisation of patented atorvastatin was considerably reduced, leading to appreciably 
greater efficiency savings for the statins in Austria than seen with  the PPIs (Table 1). 
 
The HVB in Austria was also one of the few authorities in Europe to restrict reimbursement of ARBs 
and their combinations immediately after their introduction [12, 22]. Other countries included Croatia, 
Lithuania and the Republic of Srpska [1,12, 19,20]. Western European countries including France, 
Germany, Italy, Norway, Spain, Sweden and the UK did not introduce prescribing restrictions, 
although other measures such as guidance, formularies, prescribing targets and financial incentives 
were introduced to help limit ARB prescribing [2-4,8,12,24-27]. Prescribing restrictions were though 
subsequently introduced at a later date in Sweden to further encourage the prescribing of ACEIs first 
line [25]. Under the terms of the restriction in Austria, ARBs could only be prescribed in patients 
unable to tolerate ACEIs due to for instance unacceptable dry coughing [12,20,22]. This was because 
there was no perceived difference in the effectiveness between ACEIs and ARBs, but higher 
acquisition costs for the ARBs; in addition, prospective clinical studies had shown that a dry cough 
occurred in only approximately 10% of patients prescribed ACEIs [12,20,22,28,102]. Alongside this, 
only 2 to 3% of all patients left ACEI clinical trials due to a dry cough [21,28,29]. Under the 
agreement, physicians are required to document the justification for prescribing ARBs LQWKHSDWLHQWV¶
 4 
 
notes, and these are reviewed every 2 to 3 years. Potential sanctions for abuse include physicians 
paying back to the HVB an estimate of the increased drug expenditure associated with any abuse, 
and they may no longer being able to treat Social Health Insurance patients. The latter though is 
rarely instigated in practice. However, physicians do not need the permission of the Chief Medical 
2IILFHURIWKHSDWLHQW¶VSocial Health Insurance Company before prescribing an ARB [12, 21]. This is 
unlike the situation with atorvastatin and rosuvastatin described above, where permission is needed 
before the products are reimbursed, otherwise 100% co-payment [1, 20,21,23].  
 
The regulations surrounding the prescribing ARBs in Austria were complicated by the fact that the 
restriction was based on patient reported side effects rather than a laboratory value, as seen with the 
statins [1, 12,21,22]. In addition, in practice a dry cough can occur in up to 25% of patients in selected 
populations, especially those prescribed higher doses for heart failure [30,31]. Having said this, the 
utilisation of ARBs in Austria only reached 25% of total renin-angiotensin utilisation on a DDD basis in 
2007 compared with 15% in 2001 [12,20,22]. This compares with Portugal where utilisation of ARBs 
was 44% of total renin-angiotensin utilisation in 2007, up from 20% in 2001 [12,20], reducing overall 
prescribing efficiency versus Austria (Table 1).  
 
The prescribing restrictions on ARBs, coupled with measures to lower the prices of generics and 
originators once multiple products become available (Figure 1), resulted in total expenditure on renin-
angiotensin drugs remaining relatively stable in Austria between 2001 and 2007 despite an 
appreciable increase in utilization (Table1). Total expenditure on renin-angiotensin products in Austria 
was ¼LQKDELWDQWV\HDULQYHUVXV¼LQ>2,20,22]. This compares with 
¼LQKDELWDQWV\HDUIRUUHLPEXUVHGH[SHnditure in Portugal in 2007 [12,20].    
 
There was also appreciable utilisation of renin-angiotensin fixed dose diuretic combinations (FDCs) in 
Austria between 2001 and 2007 due to limited prescribing of diuretics first line and their limited 
availability as single agents [12,20, 22]. This differs from the very limited utilisation of FDCs in 
England and Scotland, at under 2% of total renin-angiotensin utilisation on a DDD basis in 2007, as 
well as Sweden where FDCs accounted for only approximately 7% of total ACEI utilisation in 2007, 
and slightly higher for ARB FDCs [12,22]. 
 
Prescribing restrictions for losartan were eased in Austria following the availability of generic losartan 
in October 2008. However, this did not apply to the other ARBs. The care of patients prescribed ARBs 
should not be compromised by encouraging greater prescribing of losartan versus other ARBs as a 
Cochrane review concluded that all ARBs are equally effective in lowering blood pressure [32, 33], 
although others disagree [34]. However, the National Institute for Health and Clinical Excellence 
(NICE) in the UK endorsed the view of the Cochrane Collaboration in their recent guidance, stating 
that patients with hypertension can be started on either an ACEI or a low cost ARB [103,104]. There 
have been no head to head randomised trials of different ARBs claiming superiority of one ARB over 
another for heart failure [32,35,36], although higher doses of ARBs may be needed to treat heart 
failure as demonstrated by the HEAAL study with 150mg/ day of losartan versus 50mg per day 
[32,36,37]. In addition, a recent large scale registry cohort study in Denmark showed no increased 
mortality for losartan versus candesartan, despite earlier suggestions, especially when higher doses 
of losartan (100mg per day) were used [35]. Alongside this, patients in the UK have been successfully 
switched between ARBs for the management of hypertension and heart failure [32,38], Greater care 
though may be needed when switching patients with heart failure between different ARBs 
[32,104,105].  
 
Consequently, the primary objective of this study is to assess the impact of easing of the prescribing 
restriction for losartan on its subsequent utilisation. This is because up to now prescribing restrictions 
have typically EHHQDSSOLHGWRHQFRXUDJHWKHSUHVFULELQJRIKLJKHUµYDOXHG¶SURGXFWVILUVWOLQHZLWKLQD
class or related class, such as generic statins versus premium priced patented atorvastatin or 
rosuvastatin and generic ACEIs versus patented ARBs [1,12,20-22]. As a result, this study adds to 
health policy initiatives by assessing the influence on removing a prescribing restriction for one 
product within a class, whilst retaining these for all other products in the class. Other objectives 
include: (a) whether the reduction in the price of generic losartan over time is in line with previous 
findings for generic ACEIs, omeprazole or simvastatin, (b) assessing the influence of the availability of 
generic losartan coupled with the easing of its prescribing restriction on total single ARB expenditure, 
(c) analysing the utilisation of ARB combinations generally in Austria and suggesting possible reasons 
if different form previous findings, (d) suggesting additional measures that could potentially be 
 5 
 
introduced by the HVB in Austria if needed to further enhance ARB prescribing efficiency. Efficiency 
defined on this occasion as increased utilisation of multiple sourced ARBs versus patented ARBs with 
no perceived effectiveness or safety differences between them. As a result, provide guidance to other 
health authorities and health insurance agencies on potential future initiatives as they seek to further 
enhance the utilisation of multiple sourced ARBs in their countries to conserve resources. 
 
Methodology 
 
This is a quasi-experimental study [39], using a segmented time series design [40], for analyzing 
monthly reimbursed prescriptions for all patients in Austria covered by the social health insurance 
system prescribed at least one ARB alone or in combination with diuretics and other combinations 
(C09CA01 to 09, C09DA01 to 05, C09DX01 to 03) [101] in ambulatory care between October 2006, 
i.e. 2 years before generic losartan was reimbursed in Austria, to August 2011, i.e. 35 months after 
generic losartan was first reimbursed. Alongside this, total expenditure. The data source was the 
internal data warehouse of the HVB (BIG), Cube HMSTAT, based on the "maschinelle 
Heilmittelabrechnung", which covers approximately 98% of the Austrian population [8, 21, 22].  
 
We are confident that we can undertake this type of analysis as the removal of prescribing restrictions 
for losartan was the principal intervention encouraging its prescribing versus other single ARBs. This 
is because the demand-side reforms described earlier typically encourage the prescribing of a 
branded generic versus the originator to help bring generic and overall molecule prices down 
[1,21,22], with voluntary reference pricing or potentially prescribing restrictions applied to enhance 
overall prescribing efficiency for the class if needed [1,12,21]. This is illustrated by the findings with 
the PPIs, where the utilisation of esomeprazole and pantoprazole stayed relative constant before and 
after the availability of generic omeprazole, e.g. 11% of total PPIs for esomeprazole in 2007 (DDD 
basis) vs. 10% in 2002 and 39% for pantoprazole in 2007 versus 43% in 2001. The major change in 
utilisation patterns was seen with a reduction in the utilisation of rabeprazole, which was promoted 
based on its µvalue¶ until generic PPIs became available [21].  
 
Utilisation was measured LQWHUPVRI'HILQHG'DLO\'RVHZLWK'''VGHILQHGDVµthe average 
maintenance dose of a drug when used in its major indication in adults¶ZLWKWhis measure recognised 
as the international standard to assess utilisation patterns within and between countries [106]. 2011 
DDDs were used in line with international guidance [8,9,41,106], with the WHO methodology used to 
calculate the DDDs for the combination products. This was based on the principle of counting the 
combination as one dose [12,22,106]. 
 
The regression analyses were undertaken using µ5'HYHORSPHQW&RUH7HDP¶>] where the 
UHLPEXUVHGSUHVFULSWLRQVZHUHH[SODLQHGE\DYDULDEOHµ7LPH¶ZLWKLW¶VRULJLQLQ2FWREHUJHQHULF
losartan first reimbursed with its prescribing restriction removed) and DYDULDEOHµ,QWHU¶WRPRGHOWKH
change in slope following the availability of generic losartan and the removal of its prescribing 
restriction, onwards. 
 
Total costs in Euros were again used for the analysis to facilitate comparisons with previous studies 
[12, 21, 22]. This is because it is difficult in practice to disaggregate pharmacy and wholesaler mark-
ups from total costs in Austria, compounded by 20 to 25% of the Austrian population currently exempt 
from basic co-payment. As a result, total costs provides a more robust measure than estimating 
reimbursed costs using any derived formula [21]. Total costs are the price paid to the pharmacy for 
the product including the ex-factory price, the wholesaler and pharmacy mark ups but excluding VAT 
[21,22]. Total expenditure per DDD was computed for each product, including originator and generics 
where pertinent, as well as the ARB class as a whole.  
 
There has been no allowance for inflation as we wanted to compute the actual influence of the various 
policies on total expenditure as well as total expenditure/ DDD over time. In addition, the tendency of 
authorities across Europe is to cut prices of both patented drugs and generics when pharmaceutical 
expenditure is rising more rapidly than target budgets [2,7,9,11,12-15,18]. Alongside this, a number of 
European countries establish their initial prices for generics based on originator pre-patent loss prices 
including in Austria [1,2,7,9,11,12,17,19,21,22]. Consequently the use of total expenditure, as well as 
no allowance for inflation, is in line with previous publications [1,2,7,9,11,12-15,17-19,21,22]. 
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Results 
 
The lifting of the prescribing restrictions for losartan in October 2008 significantly enhanced its 
utilisation in ambulatory care (Table 2), with utilisation growing at an additional 18,567 DDDs/ month 
versus fairly constant prescribing prior to the launch of generic losartan (Figure 2).  
 
Table 2 ± Residuals and coefficients for the change in losartan utilisation before and after generic 
availability and the removal of prescribing restrictions 
 
Residuals
Minimum 1Q Median 3Q Maximum
-104819 -28514 5234 31140 165634
Coefficients Estimate Standard Error t value Significance
Intercept 523446.6 14507.7 36.081 >0.001
Time -957.4 1178.3 -0.812 0.42
Inter 18566.5 1703.9 10.896 >0.001
 
Residual standard error: 52320 on 56 degrees of freedom, Multiple R-squared: 0.9409,  
Adjusted R-squared: 0.9388 , F-statistic: 445.8 on 2 and 56 DF,  p-value: < 2.2e-16 
 
Combined with this, there was a corresponding slowing in the rate of growth in utilisation of the other 
ARBs when consolidated, which was also significant (Table 3). The rate of decline versus the trend 
seen before prescribing restrictions were lifted for losartan was 32,397DDDs/ month.  Having said 
this, the overall utilisation of other ARBs continued to increase after prescribing restrictions were 
removed for losartan (Figure 2). 
 
Table 3 - Residuals and coefficients for the change in other ARB utilisation before and after generic 
availability and the removal of its prescribing restrictions 
 
Residuals
Minimum 1Q Median 3Q Maximum
-661167 -197676 38607 144819 939862
Coefficients Estimate Standard Error t value Significance
Intercept 4869605 93287 52.2 >0.001
Time 7.035 7577 7.035 >0.001
Inter -32397 10956 -2.957 >0.01
 
Residual standard error: 336400 on 56 degrees of freedom, Multiple R-squared: 0.7475,     
 Adjusted R-squared: 0.7385 , F-statistic: 82.88 on 2 and 56 DF,  p-value: < 2.2e-16 
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Figure 2 ± Individual ARB utilisation in DDDs October 2006 to August 2011 
 
Generic losartan reimbursed and removal 
of its prescribing restrictions
 
As a result of the lifting of prescribing restrictions, the utilisation of losartan as a % of all single ARB 
utilisation increased on a DDD basis from 12% on a moving annual total (MAT) basis 12 months 
before generic losartan was available and its prescribing restrictions removed, to 16% at the end of 
the study period on a MAT basis (Table 4). Generic losartan accounted for 46% of total losartan on a 
DDD basis in August 2011. The differences in utilisation patterns of the other single ARBs after the 
lifting of the prescribing restriction for losartan may have been influenced by the different marketing 
efforts of the various ARB manufacturers. However, this needs to be substantiated by formal market 
research before any definitive conclusions can be drawn. 
 
Table 4 ± ARB utilisation on a MAT basis using DDDs October 2006 to August 2011 in DDDs (1000) 
 
Total MAT DDD 12 months 
before generic losartan
Total MAT DDD at launch 
of generic losartan
Total MAT DDD 12 months 
after generic losartan
Total MAT DDD 24 months 
after generic losartan
Total MAT DDD 35 months 
after generic losartan
% change MAT at 35 
months vs. MAT at launch
Losartan 6477.4 6236.98 7698.3 10394.1 12452.4 100
Eprosartan 1587.7 1708.1 1647.4 1539.5 1416 -17
Valsartan 9227.1 10998.3 11834.6 12154.6 12260.3 11
Candesartan 28332.6 32502 35621.8 38330.5 40071.4 23
Telmisartan 3718.5 4279.8 4611.2 4681.7 4597.99 7
Olmesartan 3432.2 4667.5 5723.9 6328.1 6695.7 43
Total 52775.5 60392.7 67137.2 73428.5 77493.8 28
% losartan vs. others 12 10 11 14 16
 
NB MAT = Moving Annual Total 
 
The increased utilisation of candesartan, olmesartan and valsartan with their higher expenditure/ DDD 
than for losartan after the availability of generic losartan (Table 5) increased total ARB expenditure 
over the study period (Table 6). 
 
Table 5 ± Expenditure/ DDD for the various ARBs (Euros) MAT ± October 2006 to August 2011 (MAT 
basis) 
 
Expenditure/ DDD MAT 12 
months before generic 
losartan
Expenditure/ DDD MAT at 
launch of generic losartan
Expenditure/ DDD MAT 12 
months after generic losartan
Expenditure/ DDD MAT 24 
months after generic losartan
Expenditure/ DDD MAT 35 
months after generic losartan
% change MAT at 35 
months vs. MAT at launch
Losartan 0.91 0.91 0.60 0.26 0.20 -78
Eprosartan 0.80 0.78 0.78 0.78 0.78 0
Valsartan 0.63 0.61 0.61 0.61 0.61 -1
Candersartan 0.59 0.59 0.59 0.58 0.57 -4
Telmisartan 0.58 0.57 0.57 0.57 0.57 0
Olmesartan 0.71 0.72 0.72 0.73 0.73 1
Total 0.65 0.64 0.61 0.55 0.53 -17
 
NB MAT = Moving Annual Total 
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Having said this, the MAT increase in total single ARB expenditure for the 12 months to August 2011 
(35 months after the availability of generic losartan) was only 7% higher than MAT expenditure at the 
launch of generic losartan (Table 6). This was despite a 28% increase in total single ARB utilisation 
during this period (Table 3), helped by a 78% reduction in MAT expenditure/ DDD for losartan during 
the course of the study period (Table 6).  
 
Table 6 ± Total expenditure (MAT) on individual ARBs (1000 Euros) October 2006 to August 2011 
MAT basis 
 
Total MAT DDD 12 months 
before generic losartan
Total MAT DDD at launch 
of generic losartan
Total MAT DDD 12 months 
after generic losartan
Total MAT DDD 24 months 
after generic losartan
Total MAT DDD 35 months 
after generic losartan
% change MAT at 35 
months vs. MAT at launch
Losartan 5869.5 5652.8 4597.9 2710.4 2494.5 -56
Eprosartan 1267.9 1335.97 1288.5 1204.1 1107.5 -17
Valsartan 5770.6 6739.2 7194.9 7379.3 7430.3 10
Candesartan 16786.9 19129.4 20844.3 22074.4 22674.5 19
Telmisartan 2138.5 2454.8 2645.8 2675 2635.1 7
Olmesartan 2448.1 3369.9 4139.2 4606.1 4901.2 45
Total 34282 38682 40711 40649 41243 7
 
 
Expenditure/ DDD for generic losartan in August 2011 was Euro 0.154 (Figure 3), 83% below the pre-
SDWHQWORVVSULFH([SHQGLWXUHLQKDELWDQWV\HDUZDV¼for the single ARBs at the end of the 
VWXG\SHULRGYHUVXV¼MXVWEHIRUHJHQHULFORVDUWDQZDVODXQFKHG, equating to a 6% increase. 
 
Figure 3 ± Expenditure/ DDD in Euros for both originator and generic losartan from August 2008 (i.e. 
just before generic availability) 
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There was continued high utilisation of ARB fixed dose combination (FDC) products in Austria 
throughout the study period (Table 7). This remained relatively stable at 46% to 49% of total single 
ARBs plus ARBs combined with a diuretic in a FDC, and 49% to 50% when all FDCs are considered 
(Table 7). As previously stated, we believe this continued high utilisation of FDCs reflects existing 
prescribing habits, coupled with the difficulties with the supply of reimbursed generic diuretics in 
Austria. However, it is difficult to fully substantiate this without formal market research. 
 
The utilisation of losartan FDC as a % of total utilisation of all losartan fell though during the study 
period from 23% MAT 12 month before the availability of generic losartan to 18% MAT by 35 months 
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after the availability of generic losartan. However, this was counter-balanced by the increased 
utilisation of all the other ARB FDCs after the availability of generic losartan, apart from valsartan 
FDCs (Table 7). These changes in utilisation patterns for the different FDCs may again have been 
influenced by the marketing efforts of the various manufacturers, with reduced activities by the 
manufacturer of originator losartan following the availability of generic losartan despite generic 
losartan FDCs not being available till March 2011. However, this again needs to be substantiated by 
formal market research before any definitive conclusions can be drawn. 
 
Table 7 ± Utilisation patterns of ARB combinations (1000 DDDs) October 2008 to August 2011 MAT 
basis 
 
Total MAT DDD 12 months 
before generic losartan
Total MAT DDD at launch 
of generic losartan
Total MAT DDD 12 months 
after generic losartan
Total MAT DDD 24 months 
after generic losartan
Total MAT DDD 35 months 
after generic losartan
% change MAT at 35 
months vs. MAT at launch
Losartan + diuretic 11597.4 11955.6 11628.9 11114.3 11873.96 -1
Eprosartan + diuretic 128.2 657.4 985.6 1120.8 1127.4 71
Valsartan + diuretic 13023.6 14353.5 14950.8 14784.6 14062.5 -2
Candesartan + diuretic 19519.1 21999.3 23549.7 24626.2 25600.2 16
Telmisartan + diuretic 3789.9 4393.2 4887.9 5092.1 5092.2 16
Olmesartan + diuretic 1756.6 3313.9 4630.4 5666.7 6541.6 97
Valsartan + amlodipine 0.2 1571.7 3793 4966.3 5305.1 238
Olmesartan + amlodipine 0 0 85.5 2471.6 4117.4 NA
Telmisartan + amlodipine 0 0 0 0 13.4 NA
valsartan, amlodipine + 
hydrochlorothiazide 0 0 0 369.7 2941.5 NA
olmesartan, amlodipine + 
hydrochlorothiazide 0 0 0 0 3.9 NA
Total ARB + diuretic 
combinations 49815 56673 60633 62774 67243 19
% losartan combination vs. 
All ARBs + diuretic 23 21 19 18 18
Total all ARB combinations 49815 58245 64512 70212 76679 32
Total single ARBs 52776 60392.8 67137.2 73428.5 77494
Total single ARBs + diuretic 
combinations 102590 117066 127771 136203 144737
Total all ARBs 102591 118637 131649 143641 154173
% combination ARB and 
diuretics vs. all ARBs 49 48 47 46 46
% all ARB combinations vs. 
all ARBs 49 49 49 49 50
 
 
Discussion and future implications  
 
The findings demonstrate that the lifting of prescribing restriction for losartan significantly enhanced its 
utilisation versus the other ARBs (P> 0.001), with the rate of growth in the utilisation of other ARBs 
declining (P>0.01) (Tables 2 and 3).  Having said this, the utilisation of the other ARBs in totality also 
increased following the availability of generic losartan (Figure 1), especially candesartan, olmesartan 
and valsartan (Table 4). However, the overall rate of their increase declined from the utilisation 
pattern seen before generic losartan (Figure 1). We accept that there are limitations with this finding 
as we have not been able to fully disassociate the influence of the changes in the prescribing 
restrictions for losartan with ongoing reforms to enhance the prescribing of generics. However as 
discussed earlier, these measures are aimed principally at increasing the prescribing of generics 
versus originators, with additional measures such as voluntary reference pricing and prescribing 
restrictions instigated to enhance prescribing efficiency of the class if needed. This is further 
confirmed by one of the main subjects among Quality Circles of ambulatory care physicians belonging 
to local Health Insurance Funds was to increase their use of generics [42]. Over a 3 year period, the 
prescribing of generics increased from 34% to 50% of products where a generic was available [42]. 
 
We believe the findings reflect that the majority of new patients are preferentially started on losartan, 
thereby reducing the need for extensive documentation among GPs before prescribing another ARB. 
In addition, we believe there has also been some switching of existing ARB patients to losartan when 
patients re-visit their GPs, as total ARB utilisation grew by 17.10mn DDDs from 12 months MAT 
before generic losartan to 35 months MAT after, with losartan accounting for an appreciable 
proportion of this increase at 6.215mn DDDs (Table 4). However, it is difficult to substantiate this 
without access to specific patient records and/ or specific market research among physicians. This 
was unlike the situation in Sweden when assessing the influence of the prescribing restrictions on the 
subsequent utilisation on ARBs first line [25], which is a recognised weakness of this study. 
 
One potential reason for some switching, but not a high level with losartan only accounting for 16% of 
total single ARB utilisation on a MAT DDD basis 35 months after the lifting of its prescribing 
restrictions (Table 4), if our perceptions are correct, could be that ARB prescribing habits are 
ingrained after several years of prescribing restrictions for ARBs, and it is difficult to appreciably break 
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these without specific activities. This mirrors the situation in Sweden where the imposition of 
prescribing restrictions for atorvastatin and rosuvastatin, along with the removal of lower strength 
atorvastatin and rosuvastatin 6 years after generic simvastatin, had limited influence apart from 
appreciably reducing the prescribing of lower strength atorvastatin and rosuvastatin [43].  
 
Consequently to further influence future prescribing patterns, including both new and existing patients, 
particularly where products are not the most prescribed drug in a class, additional specific activities 
may be needed. These could include delisting of patented ARBs from the reimbursement list, which 
as the situation in Denmark, or active switching policies from patented ARBs to multiple sourced 
ARBs as seen in some UK Primary Care Trusts [Personal communication Andrew Martin]. 
Alternatively in the case of Austria, instigate formal prior approval for existing patented ARBs as more 
ARBs lose their patent, mirroring the situation with atorvastatin and rosuvastatin [20,21], with all ARBs 
being seen as essentially equal at optimal doses [31-33, 35-37,103]. This helped accelerate the 
utilisation of simvastatin over atorvastatin when introduced in Austria [20,21], appreciably enhancing 
prescribing efficiency (Table 1). The potential restrictions for existing patented ARBs is now being 
actively considered to enhance prescribing efficiency, especially given the differences in expenditure/ 
DDD between generic and patented ARBs (Table 5). 
 
As expected, increasing use of losartan at reduced expenditure/ DDD (Table 5, Figure 3), limited the 
increase in ARB expenditure by the end of the study period (Table 6), versus an appreciably higher 
increase in single ARB utilisation (Table 4).  
 
Total expenditure/ DDD for both the originator and generic losartan fell in line with expectations 
(Figure 3) [1, 21,22]. However, the mirroring of the reduction in total expenditure/ DDD for both the 
originator and generic losartan (Figure 3) may explain the still high utilisation of the originator losartan 
some 35 months after the availability of generic losartan, at 54% of total losartan utilisation. This is 
unlike the situation with generic omeprazole and generic simvastatin at 90% and 95% of total 
utilisation for the respective molecules in 2007 [21]. This is despite the ongoing initiatives to enhance 
the prescribing of generics versus originators once multiple sources are available described earlier 
[1,21,22,42]. 
 
In conclusion, we believe the easing of prescribing restrictions for losartan significantly enhanced its 
utilisation versus other ARBs, although these continued to grow. We believe this is the first time that 
the easing of prescribing restrictions has been reported for one drug within a class certainly in Austria 
and possibly among Western European countries. Generally, studies have described the influence of 
instigating prescribing restrictions [8,9,12,20-23, 25, 43-45].The lifting of the prescribing restrictions 
for losartan, coupled with ongoing measures to reduce the price of both originator and branded 
generic losartans once multiple sources became available, helped enhance ARB prescribing 
efficiency. As a result, providing guidance to other countries seeking further initiatives to enhance 
their ARB prescribing efficiency. However, additional reforms are needed to further improve ARB 
prescribing efficiency, especially when prescribing habits are ingrained. This mirrors the results from 
other studies where multiple demand side measures are needed to appreciably change utilisation 
patterns given the complexities of prescribing decisions [4,8,9,12,15,41,46-48].  
 
Key issues 
 
x The restrictions limiting the prescribing of ARBs in ambulatory care to patients unable to tolerate 
the side-effects of ACEIs helped reduce their utilisation in practice. These restrictions were lifted 
for losartan once generics were launched, but remained for all other patented ARBs 
x The lifting of prescribing restrictions significantly enhanced the utilisation of losartan in ambulatory 
care, increased its utilisation as a % of single ARBs from 12% (MAT DDDs) just before generic 
availability to 16% at the end of the study period (35 months MAT). This included new patients 
prescribed losartan as their first ARB as well as patients switched from other ARBs 
x Expenditure/ DDD for generic losartan was 83% below pre-patent loss prices by the end of the 
study period. Expenditure/ DDD for the originator also reduced, resulting in overall expenditure/ 
DDD for losartan reducing by 78% during the study period (MAT basis). As a result, total 
expenditure/ 1000 inhabitants/ year for single ARBs only increased by 7% versus pre-patent loss 
prices by the end of the study period compared with a 28% increase in utilisation 
x There was appreciable utilisation of ARB fixed dose combinations (FDCs), mirroring previous 
findings, at 49% to 50% of total renin-angiotensin inhibitor drugs (DDD basis)   
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x The results show that lifting prescribing restrictions for one drug in a class significantly enhances 
it utilisation. However, additional reforms will be needed to further improve prescribing efficiency 
when prescribing habits are ingrained, mirroring the findings in other countries. 
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